Found: 6
Select item for more details and to access through your institution.
Sustained reduction of serum neurofilament light chain over 7 years by alemtuzumab in early relapsing–remitting MS.
- Published in:
- Multiple Sclerosis Journal, 2022, v. 28, n. 4, p. 573, doi. 10.1177/13524585211032348
- By:
- Publication type:
- Article
Efficacy of alemtuzumab over 6 years in relapsing–remitting multiple sclerosis patients who relapsed between courses 1 and 2: Post hoc analysis of the CARE-MS studies.
- Published in:
- Multiple Sclerosis Journal, 2020, v. 26, n. 13, p. 1719, doi. 10.1177/1352458519881759
- By:
- Publication type:
- Article
(DXT65) Longitudinal Disability Follow-up in Patients with 6-Month Confirmed Disability Improvement or Worsening in the CARE-MS and Extension Studies.
- Published in:
- International Journal of MS Care, 2020, v. 22, n. S2, p. 39
- By:
- Publication type:
- Article
Confirmed 6-Month Disability Improvement and Worsening Correlate with Long-term Disability Outcomes in Alemtuzumab-Treated Patients with Multiple Sclerosis: Post Hoc Analysis of the CARE-MS Studies.
- Published in:
- Neurology & Therapy, 2021, v. 10, n. 2, p. 803, doi. 10.1007/s40120-021-00262-3
- By:
- Publication type:
- Article
Quality of Life Improves with Alemtuzumab Over 6 Years in Relapsing-Remitting Multiple Sclerosis Patients with or without Autoimmune Thyroid Adverse Events: Post Hoc Analysis of the CARE-MS Studies.
- Published in:
- Neurology & Therapy, 2020, v. 9, n. 2, p. 443, doi. 10.1007/s40120-020-00191-7
- By:
- Publication type:
- Article
Functional MRI of Letter Cancellation Task Performance in Older Adults.
- Published in:
- Frontiers in Human Neuroscience, 2019, p. N.PAG, doi. 10.3389/fnhum.2019.00097
- By:
- Publication type:
- Article